Literature DB >> 1425868

Factors in hydrazine formation from isoniazid by paediatric and adult tuberculosis patients.

W L Gent1, H I Seifart, D P Parkin, P R Donald, J H Lamprecht.   

Abstract

An HPLC method is described for measurement of plasma hydrazine (Hz) concentrations (CHz) at the same time as isoniazid (INH) levels (CINH). Study has been made of CHz during 2-5 after dose in healthy adults (A, n = 34), in adult pulmonary TB patients (B, n = 18) and in paediatric tuberculous meningitis patients (C, n = 25). Although the population has about equal proportions of 'slow' (52%) and 'fast' acetylators, in none of the groups could a correlation be shown between CHz levels or rates of Hz accumulation and any measure of acetylator type. Consequently Hz must be derived both from INH and from its metabolites during the first hours post-dose. For group A and ca. 70% of groups B and C a constant and maximal fraction of dose (ca. 0.6% for adults and 0.4% for paediatric patients) appeared as Hz at 4-5 h. For group B patients small pre-dose concentrations increased with duration of treatment. Four patients in group B showed the highest levels of CHz and rates of Hz accumulation some three times greater than the rest; all four had been identified as alcoholics and one showed evidence of hepatotoxicity at CHz (5 h) = 1.3% of dose. Amongst group C (9/25) episodes of high CHz greater than 0.5% of dose occurred during the first weeks of treatment and one developed CHz ca. 100 ng/ml = 1.3% of dose coincidentally with indications of hepatic damage.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425868     DOI: 10.1007/bf01740658

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Pharmacokinetics of isoniazid metabolism in man.

Authors:  G A Ellard; P T Gammon
Journal:  J Pharmacokinet Biopharm       Date:  1976-04

2.  The determination of isoniazid and its metabolites acetylisoniazid, monoacetylhydrazine, diacetylhydrazine, isonicotinic acid and isonicotinylglycine in serum and urine.

Authors:  G A Ellard; P T Gammon; S M Wallace
Journal:  Biochem J       Date:  1972-02       Impact factor: 3.857

3.  Self-induction of rifampicin metabolism in man.

Authors:  C Immanuel; K Jayasankar; A S Narayana; G R Sarma
Journal:  Indian J Med Res       Date:  1985-11       Impact factor: 2.375

4.  [Microanalysis of plasma isoniazid and acetylisoniazid by high performance liquid chromatography].

Authors:  C Lacroix; G Laine; J P Goulle; J Nouveau
Journal:  J Chromatogr       Date:  1984-04-13

5.  Hepatic toxicity during chemotherapy for severe tuberculosis meningitis.

Authors:  P R Donald; J F Schoeman; A O'Kennedy
Journal:  Am J Dis Child       Date:  1987-07

6.  Plasma hydrazine concentrations in man after isoniazid and hydralazine administration.

Authors:  I A Blair; R Mansilla Tinoco; M J Brodie; R A Clare; C T Dollery; J A Timbrell; I A Beever
Journal:  Hum Toxicol       Date:  1985-03

7.  Risk factors for isoniazid (NIH)-induced liver dysfunction.

Authors:  D S Dickinson; W C Bailey; B I Hirschowitz; S J Soong; L Eidus; M M Hodgkin
Journal:  J Clin Gastroenterol       Date:  1981-09       Impact factor: 3.062

Review 8.  Clinical pharmacokinetics of isoniazid.

Authors:  W W Weber; D W Hein
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

9.  Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin.

Authors:  G R Sarma; C Immanuel; S Kailasam; A S Narayana; P Venkatesan
Journal:  Am Rev Respir Dis       Date:  1986-06

10.  Oxidation of hydrazine metabolites formed from isoniazid.

Authors:  B H Lauterburg; C V Smith; E L Todd; J R Mitchell
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

View more
  10 in total

Review 1.  A guide to the management of tuberculosis in patients with chronic liver disease.

Authors:  Radha K Dhiman; Vivek A Saraswat; Harshal Rajekar; Chandrasekhar Reddy; Yogesh K Chawla
Journal:  J Clin Exp Hepatol       Date:  2012-09-21

2.  Lack of liver injury in Wistar rats treated with the combination of isoniazid and rifampicin.

Authors:  Imir G Metushi; Jack Uetrecht
Journal:  Mol Cell Biochem       Date:  2013-10-23       Impact factor: 3.396

Review 3.  Hepatotoxic effects of therapies for tuberculosis.

Authors:  Bahaa E Senousy; Sanaa I Belal; Peter V Draganov
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-08-31       Impact factor: 46.802

4.  Quantification of Hydrazine in Human Urine by HPLC-MS-MS.

Authors:  Samantha L Isenberg; Melissa D Carter; Brian S Crow; Leigh Ann Graham; Darryl Johnson; Nick Beninato; Kandace Steele; Jerry D Thomas; Rudolph C Johnson
Journal:  J Anal Toxicol       Date:  2016-03-13       Impact factor: 3.367

Review 5.  Antitubercular therapy in patients with cirrhosis: challenges and options.

Authors:  Naveen Kumar; Chandan Kumar Kedarisetty; Sachin Kumar; Vikas Khillan; Shiv Kumar Sarin
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

6.  Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism.

Authors:  Mohammad Sistanizad; Ebrahim Azizi; Hosein Khalili; Mahboobeh Hajiabdolbaghi; Kheirollah Gholami; Reza Mahjub
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

7.  Bypassing the compromised mitochondrial electron transport with methylene blue alleviates efavirenz/isoniazid-induced oxidant stress and mitochondria-mediated cell death in mouse hepatocytes.

Authors:  Kang Kwang Lee; Urs A Boelsterli
Journal:  Redox Biol       Date:  2014-03-13       Impact factor: 11.799

Review 8.  Isoniazid metabolism and hepatotoxicity.

Authors:  Pengcheng Wang; Komal Pradhan; Xiao-Bo Zhong; Xiaochao Ma
Journal:  Acta Pharm Sin B       Date:  2016-08-03       Impact factor: 11.413

9.  Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis.

Authors:  Zenya Saito; Yugo Kaneko; Akira Kinoshita; Yusuke Kurita; Kyuto Odashima; Tsugumi Horikiri; Yutaka Yoshii; Aya Seki; Yoshitaka Seki; Hiroshi Takeda; Kazuyoshi Kuwano
Journal:  BMC Infect Dis       Date:  2016-11-11       Impact factor: 3.090

10.  Effect of subclinical, clinical and supraclinical doses of calcium channel blockers on models of drug-induced hepatotoxicity in rats.

Authors:  Iniviefien B Okwa; Abidemi J Akindele; Esther O Agbaje; Oladoyin T Oshinuga; Chidozie C Anunobi; Olufunmilayo O Adeyemi
Journal:  EXCLI J       Date:  2013-03-14       Impact factor: 4.068

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.